Full Press Release Details
Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update
Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"),
a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced
financial results for the quarter ended September 30, 2025, and provided an update on recent operational achievements and upcoming
Quarter & Recent Corporate Highlights
- Intranasal therapy for malignant recurrent WHO Grade 3 /4 IDH1 Astrocytoma
- Bio-conjugated therapy for primary and metastatic brain tumors
- Pediatric brain tumor trial initiated with patient recruitment underway.
Heshmatpour, Executive Chairman, President & CEO of NeOnc Technologies Holdings, Inc., commented:
2025 was a defining quarter for NeOnc-one that firmly positions us at the forefront of innovation in CNS oncology. We delivered
exceptional clinical progress, highlighted by highly encouraging Phase 2a data from our NEO100 program that signal a potential paradigm
shift for patients battling recurrent high-grade gliomas. We also achieved a major regulatory milestone with FDA clearance to advance
our second asset, NEO212, into Phase 2 trials, further strengthening the depth and momentum of our pipeline.
and financially, we reinforced the foundation for long-term global growth. We secured meaningful support from the NIH and finalized a
landmark $50 million commitment through our NuroMENA subsidiary-an agreement that accelerates our expansion across the Middle East
and positions NeOnc as a clinical and scientific partner of choice in the region. This progress is further strengthened by the appointment
of H.H. Sheikh Nahyan bin Zayed Al Nahyan as Executive Chairman of NuroMENA, whose leadership and vision bring extraordinary strategic
value and elevate our international standing.
a fortified leadership team, heightened market visibility, and multiple significant clinical catalysts ahead, NeOnc enters the next stage
of execution with confidence. We are advancing life-changing therapies for patients who urgently need new options, while driving meaningful
value creation for our shareholders.
NEONC TECHNOLOGIES HOLDINGS, INC.
Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous
system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company's
NEO drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections
extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers
and in clinical trials treating malignant gliomas. NeOnc's NEO100 and NEO212 therapeutics are in Phase II human
clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed
an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications
related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological
more about NeOnc and its pioneering technology, visit neonc.com.
Cautions Regarding Forward Looking Statements
press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology
such as "may," "will," "should," "intend," "expect," "plan,"
"budget," "forecast," "anticipate," "believe," "estimate," "predict,"
"potential," "continue," "evaluating," or similar words. Statements that contain these words should
be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other
forward-looking information.
of forward-looking statements include, among others, statements regarding the potential positive effects of NEO100. These statements
reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated.
The "Risk Factors" section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission,
along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may
cause our actual results to differ materially from the forward-looking statements herein. We assume no obligation to revise or update
any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable
securities laws and regulations.
and NEO "212" are registered trademarks of NeOnc Technologies Holdings, Inc.